Impact of short-term haart initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Moreau, Marina ^a   Tortorec, Anna ^a   Deleage, Claire ^a   Brown, Charles ^c   Denis, Hélène ^a   Satie, Anne Pascale ^a   Bourry, Olivier ^b,d   Deureuddre Bosquet, Nathalie ^b,d   Roques, Pierre ^b,d   Grand, Roger ^b,d   Le Grand, Nathalie ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; INDINAVIR; LAMIVUDINE; VIRUS DNA; ZIDOVUDINE; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IN SITU HYBRIDIZATION; INFLAMMATORY INFILTRATE; MACACA FASCICULARIS; MALE; MALE GENITAL SYSTEM; NONHUMAN; POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD; VIRUS SHEDDING; ANIMAL; DRUG EFFECT; GENETICS; SIMIAN IMMUNODEFICIENCY VIRUS; SPERM; VIROLOGY;

ANIMALIA; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENITALIA, MALE; INDINAVIR; LAMIVUDINE; MACACA FASCICULARIS; MALE; RNA, VIRAL; SEMEN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; ZIDOVUDINE;

EID: 84861209845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037348     Document Type: Article

References (66)

1. Halfon P, Giorgetti C, Khiri H, Penaranda G, Terriou P, et al. (2010) Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS One 5: e10569.
2. Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, et al. (2010) Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 54: 4910-4913.
3. Sheth PM, Kovacs C, Kemal KS, Jones RB, Raboud JM, et al. (2009) Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. Aids 23: 2050-2054.
4. Marcelin AG, Tubiana R, Lambert-Niclot S, Lefebvre G, Dominguez S, et al. (2008) Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. Aids 22: 1677-1679.
5. Pasquier CJ, Moinard N, Saune K, Souyris C, Lavit M, et al. (2008) Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract. Aids 22: 1894-1896.
6. Zhang HD, Beumont GM, Livornese L, Van Uitert Jr, Henning B, Pomerantz KR.J., (1998) Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 339: 1803-1809.
7. Le Tortorec A, Dejucq-Rainsford N, (2010) HIV infection of the male genital tract-consequences for sexual transmission and reproduction. Int J Androl 33: e98-108.
8. Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, et al. (2010) HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog 6: 1001053.
9. Pillai SK, Good B, Pond SK, Wong JK, Strain MC, et al. (2005) Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 79: 1734-1742.
10. Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, et al. (2004) Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. Aids 18: 447-457.
11. Whitney JB, Hraber PT, Luedemann C, Giorgi EE, Daniels MG, et al. (2011) Genital tract sequestration of SIV following acute infection. PLoS Pathog 7: e1001293.
12. Deleage C, Moreau M, Rioux-Leclercq N, Ruffault A, Jegou B, et al. (2011) Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo. Am J Pathol 179: 2397-2408.
13. Le Tortorec A, Satie AP, Denis H, Rioux-Leclercq N, Havard L, et al. (2008) Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. Retrovirology 5: 119.
14. Le Tortorec A, Le Grand R, Denis H, Satie AP, Mannioui K, et al. (2008) Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS ONE 3: e1792.
15. Shehu-Xhilaga M, Kent S, Batten J, Ellis S, Van der Meulen J, et al. (2007) The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. Retrovirology 4: 7.
16. Roulet V, Satie AP, Ruffault A, Le Tortorec A, Denis H, et al. (2006) Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro. Am J Pathol 169: 2094-2103.
17. Willey S, Roulet V, Reeves JD, Kergadallan ML, Thomas E, et al. (2003) Human Leydig cells are productively infected by some HIV-2 and SIV strains but not by HIV-1. Aids 17: 183-188.
18. Paranjpe S, Craigo J, Patterson B, Ding M, Barroso P, et al. (2002) Subcompartmentalization of HIV-1 Quasispecies between Seminal Cells and Seminal Plasma Indicates Their Origin in Distinct Genital Tissues. AIDS Res Hum Retroviruses 18: 1271-1280.
19. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, et al. (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28: 655-660.
20. Livni E, Berker M, Hillier S, Waller SC, Ogan MD, et al. (2004) Preparation and pharmacokinetics of 11C labeled stavudine (d4T). Nucl Med Biol 31: 613-621.
21. Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, et al. (2003) Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol 77: 12479-12493.
22. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, et al. (2010) Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 7: 78.
23. Dioszeghy V, Benlhassan-Chahour K, Delache B, Dereuddre-Bosquet N, Aubenque C, et al. (2006) Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression. J Virol 80: 236-245.
24. Bourry O, Brochard P, Souquiere S, Makuwa M, Calvo J, et al. (2009) Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. Aids 23: 447-454.
25. Puaux AL, Marsac D, Prost S, Singh MK, Earl P, et al. (2004) Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles. Vaccine 22: 3535-3545.
26. Thiebot H, Vaslin B, Derdouch S, Bertho JM, Mouthon F, et al. (2005) Impact of bone marrow hematopoiesis failure on T-cell generation during pathogenic simian immunodeficiency virus infection in macaques. Blood 105: 2403-2409.
27. Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, et al. (2008) Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 46: 2206-2211.
28. Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, et al. (1997) A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol 71: 1608-1620.
29. Hirsch VM, Dapolito G, Johnson PR, Elkins WR, London WT, et al. (1995) Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol 69: 955-967.
30. Brown CR, Czapiga M, Kabat J, Dang Q, Ourmanov I, et al. (2007) Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J Virol 81: 5594-5606.
31. Le Tortorec A, Dejucq-Rainsford N, (2010) Infection of semen-producing organs by HIV and role in virus dissemination. Med Sci 26: 861-868.
32. Thiebot H, Louache F, Vaslin B, de Revel T, Neildez O, et al. (2001) Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection. J Virol 75: 11594-11602.
33. Le Grand R, Vaslin B, Larghero J, Neidez O, Thiebot H, et al. (2000) Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. Aids 14: 1864-1866.
34. Pasquier C, Moinard N, Sauné K, Daudin M, Trancart S, et al. (2012) Antiviral effect of maraviroc in semen: a case report Antiviral Therapy in press.
35. Pasquier C, Saune K, Raymond S, Moinard N, Daudin M, et al. (2009) Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol 47: 2883-2887.
36. Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, et al. (2002) Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. Aids 16: 39-45.
37. Gunthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, et al. (2001) Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 183: 1318-1327.
38. Mayer KH, Boswell S, Goldstein R, Lo W, Xu C, et al. (1999) Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 28: 1252-1259.
39. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, et al. (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Jama 282: 1627-1632.
40. Zhang H, Dornadula G, Beumont M, Livornese LJ, Van Uitert B, et al. (1998) Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 339: 1803-1809.
41. Taylor S, Davies S, (2010) Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS 5: 335-343.
42. Annamalai L, Bhaskar V, Pauley DR, Knight H, Williams K, et al. (2010) Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques. Am J Pathol 177: 777-791.
43. Kotler DP, Shimada T, Snow G, Winson G, Chen W, et al. (1998) Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. Aids 12: 597-604.
44. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, et al. (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84: 2913-2922.
45. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
46. Crowe S, Zhu T, Muller WA, (2003) The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 74: 635-641.
47. Aquaro S, Svicher V, Schols D, Pollicita M, Antinori A, et al. (2006) Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol 80: 1103-1110.
48. Miller CJ, Vogel P, Alexander NJ, Dandekar S, Hendrickx AG, et al. (1994) Pathology and localization of simian immunodeficiency virus in the reproductive tract of chronically infected male rhesus macaques. Lab Invest 70: 255-262.
49. Baskerville A, Cook RW, Dennis MJ, Cranage MP, Greenaway PJ, (1992) Pathological changes in the reproductive tract of male rhesus monkeys associated with age and simian AIDS. J Comp Pathol 107: 49-57.
50. Pudney J, Anderson D, (1991) Orchitis and human immunodeficiency virus type 1 infected cells in reproductive tissues from men with the acquired immune deficiency syndrome. Am J Pathol 139: 149-160.
51. Shen C, Ding M, Craigo JK, Tarwater P, Chatterjee R, et al. (2010) Genetic characterization of HIV-1 from semen and blood from clade C-infected subjects from India and effect of therapy in these body compartments. Virology 401: 190-196.
52. Leruez-Ville M, Dulioust E, Costabliola D, Salmon D, Tachet A, et al. (2002) Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). Aids 16: 486-488.
53. Barroso PF, Schechter M, Gupta P, Melo MF, Vieira M, et al. (2000) Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med 133: 280-284.
54. Zhou S, Ou R, Huang L, Price GE, Moskophidis D, (2004) Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J Virol 78: 3578-3600.
55. Caufour P, Le Grand R, Cheret A, Neildez O, Thiebot H, et al. (2001) Longitudinal analysis of CD8(+) T-cell phenotype and IL-7, IL-15 and IL-16 mRNA expression in different tissues during primary simian immunodeficiency virus infection. Microbes Infect 3: 181-191.
56. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16: 460-465.
57. Benito JM, Lopez M, Lozano S, Martinez P, Gonzalez-Lahoz J, et al. (2004) CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 20: 227-233.
58. Cohen Stuart JW, Hazebergh MD, Hamann D, Otto SA, Borleffs JC, et al. (2000) The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 25: 203-211.
59. Wang X, Xu H, Alvarez X, Pahar B, Moroney-Rasmussen T, et al. (2011) Distinct Expression Patterns of CD69 in Mucosal and Systemic Lymphoid Tissues in Primary SIV Infection of Rhesus Macaques. PLoS One 6: e27207.
60. Kwa S, Kannanganat S, Nigam P, Siddiqui M, Shetty RD, et al. (2011) Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques. Blood 118: 2763-2773.
61. Clay CC, Rodrigues DS, Harvey DJ, Leutenegger CM, Esser U, (2005) Distinct chemokine triggers and in vivo migratory paths of fluorescein dye-labeled T Lymphocytes in acutely simian immunodeficiency virus SIVmac251-infected and uninfected macaques. J Virol 79: 13759-13768.
62. Haase AT, (2005) Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5: 783-792.
63. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, et al. (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79: 9217-9227.
64. Sellier P, Mannioui A, Bourry O, Dereuddre-Bosquet N, Delache B, et al. (2010) Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 5: e10570.
65. Yeni P, (2008) Prise en charge médicale des personnes infectees par le VIH. Recommandation du groupe d'experts Paris Flammarion Médecine Sciences.
66. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, et al. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 54: 1-20.